Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01722864 · ClinicalTrials.gov registry record · Phase 3

Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)

A Phase 3 study, sponsored by Mallinckrodt.

Completed
Registry status
Phase 3
Development phase
153
Enrollment target

NCT01722864 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 153 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01722864, a Phase 3 study, has completed, sponsored by Mallinckrodt.

COMPLETED
Registry status
Phase 3
Development phase
153 participants
Enrollment target

Study Summary

A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.

Interventions

  • DRUG COV155

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2012-11
Est. Completion 2013-08
Phase Phase 3

Sponsor

Mallinckrodt

69 total trials

What the Registry Record Tells You About NCT01722864

The ClinicalTrials.gov registry entry for NCT01722864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which COV155 is the first listed.

NCT01722864 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01722864 about?

NCT01722864 is a clinical study titled "Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)". A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.

What is the current status of trial NCT01722864?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2012-11. Estimated completion is 2013-08.

What interventions are being tested in trial NCT01722864?

The interventions under investigation include: COV155 (DRUG).

Who is sponsoring clinical trial NCT01722864?

This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.